Cut through the noise, find the signal: Intelligence for serious healthcare leaders
Analysis updated November 9, 2026
OPPS is not an innovation model — it is the foundational payment architecture governing how Medicare reimburses the majority of hospital outpatient and ambulatory surgical center services. Understanding its structural mechanics is a prerequisite for every downstream strategic decision in outpatient care.
The hybrid payment logic creates persistent cross-subsidy tension. OPPS operates as a dual-track system: some services are packaged into Ambulatory Payment Classification (APC) rates (prospective, all-in), while others — particularly separately payable drugs with status indicators "G" or "K" — are reimbursed retrospectively on an ASP-based fee schedule. This means a single outpatient encounter can generate both fixed-rate and cost-sensitive revenue streams that behave completely differently under volume and cost pressure. The CY 2027 preliminary ratesetting data confirms this dynamic in concrete terms: esketamine administration (G2082/G2083) generates geometric mean costs of $1,171 and $1,644 respectively, while the APC rates they fall within ($1,001–$1,100 and $1,601–$1,700) may not fully recover those costs depending on cost report vintage and case mix.
The CY 2026 resumption of IPO list elimination is the single most consequential structural change embedded in this ruleset. After halting the planned elimination in CY 2022, CMS finalized a renewed phased elimination in the CY 2026 OPPS/ASC final rule (90 FR 53448). The practical effect: procedures historically ring-fenced for inpatient Part A payment will migrate to outpatient status, creating new APC assignments and exposing hospitals to lower OPPS rates for high-complexity cases. Critically, the indefinite Two-Midnight medical review exemption for procedures removed from the IPO list was preserved — CMS will not initiate utilization scrutiny until a service is "more commonly performed in the outpatient setting for the Medicare population." That exemption provides a meaningful compliance buffer during transition, but it is discretionary and revocable.
The September 1, 2025 shift of patient status reviews from BFCC-QIOs to MACs under the Targeted Probe and Educate (TPE) program materially changes audit risk calculus. MACs review on a sampling basis under Medicare Program Integrity Manual Chapter 6, Exhibit 48. TPE is iterative — a failed probe round triggers additional rounds and potential pre-payment review. Hospitals with high short-stay inpatient admission rates are now in a different regulatory environment than they were pre-September 2025, and the operational response (utilization management staffing, clinical documentation integrity infrastructure) must reflect that shift.
Section 603 off-campus provider-based department policy continues to bifurcate the market. Excepted PBDs billing under OPPS retain their payment advantage; non-excepted PBDs bill at Physician Fee Schedule rates, a structurally lower payment basis. The extraordinary circumstance relocation exception remains narrow by design — CMS explicitly stated these exceptions will be "limited and rare." Health systems contemplating campus reconfiguration, including those responding to seismic code requirements or disaster recovery, must treat the Regional Office review process (30-day submission window post-extraordinary circumstance) as a hard operational deadline with significant revenue consequences if missed.
Drug discard exposure under JW/JZ is an underappreciated revenue integrity risk with direct bottom-line impact. Effective October 1, 2023, claims for separately payable OPPS drugs from single-dose containers that omit the JW or JZ modifier may be returned unprocessable. The refund mechanism under section 90004 of the Infrastructure Investment and Jobs Act (Public Law 117-9) means that manufacturer refunds to CMS are calculated directly from JW modifier data — and prior to the JZ modifier requirement, CMS documented "observed low compliance" with JW reporting. Hospitals should assume MAC audit exposure on any high-volume, high-cost separately payable drug (status indicators G or K) where modifier documentation is inconsistent. The financial exposure is claims-level and compounding: a high-volume biologic at even modest per-unit cost generates significant aggregate refund liability.
New Technology APC payment rates reveal specific service lines where outpatient economics are marginal or negative. From the CY 2027 preliminary ratesetting data (CY 2025 claims, January–September):
For ASCs, the separately payable drug threshold (payment indicator K2) determines which drug costs are recoverable. Packaged drugs (N1) are absorbed into the procedure rate — meaning procedure selection and supply chain discipline are the only levers. ASCs considering service line expansion into drug-intensive procedures (e.g., intravitreal injections, immunotherapy administration) must model the K2 vs. N1 assignment for each proposed drug before committing capital.
Non-BLA skin substitutes as of January 1, 2026 are reimbursed as incident-to supplies, not separately payable biologics. This eliminates JW/JZ billing on those products and removes the discarded drug payment for wasted units — a direct margin compression for wound care programs that previously recovered discard amounts on high-cost skin substitute products.
Large integrated health systems with excepted off-campus PBDs hold a durable structural advantage that smaller community hospitals and independent physician groups cannot replicate. OPPS rates exceed PFS rates for identical services in most clinical categories — the gap is particularly pronounced in procedural and imaging APCs. This advantage compounds over time as non-excepted sites remain locked at PFS rates absent qualifying for limited exceptions.
The IPO list elimination creates an asymmetric opportunity for high-volume ASCs. As procedures migrate off the inpatient-only list, ASCs with the infrastructure to perform them capture cases that previously generated zero ASC revenue. The exemption from Two-Midnight medical review provides cover during the utilization ramp. However, ASCs lack the cost report infrastructure that hospitals use to influence APC ratesetting — their economic exposure is price-taker risk if CMS sets APC rates below true ambulatory procedure costs.
Medicare Advantage plans must operationalize the MAC-driven patient status review shift. MA plans are subject to Two-Midnight rule requirements per the CY 2024 MA final rule. With MACs now conducting TPE reviews for short inpatient stays, MA plan prior authorization and concurrent review protocols that deviate from Two-Midnight benchmarks create legal exposure and claims dispute risk. Plans that have built UM criteria around BFCC-QIO review patterns need to recalibrate against MAC TPE methodology.
Physicians: The Two-Midnight rule's case-by-case exception for sub-two-midnight stays (finalized in CY 2016) preserves clinical judgment authority, but MAC TPE creates a new documentation burden. The physician's stated expectation of hospital duration — and the medical record support for that expectation — is now the primary audit target. Hospitalists and admitting physicians at institutions with high short-stay rates face increased query burden and documentation reconciliation demands.
Health Systems: The IPO list resumption requires immediate service line and CDI response. Procedures migrating out of the IPO list need new care pathway design (outpatient infrastructure, anesthesia coverage, recovery protocols) and APC payment validation before volume commitments are made. Systems with off-campus PBDs must maintain detailed compliance calendars for the extraordinary circumstance relocation exception — missing the 30-day submission window is an unappealable loss of excepted status.
Hospitals: JW/JZ compliance is now a revenue integrity imperative, not a billing technicality. The combination of MAC audit risk (post-October 2023) and manufacturer refund calculation based on JW data means hospitals must treat modifier adherence as a financial control, not a coding preference. The non-BLA skin substitute reclassification as of January 1, 2026 requires immediate claims process redesign for wound care and dermatology outpatient programs.
Payer/MA Plans: The telehealth extensions through September 30, 2025 (geographic flexibility, audio-only, expanded practitioner eligibility including PTs, OTs, SLPs) create a defined expiration cliff. MA plans with telehealth benefit designs built on these flexibilities must have contingency protocols for October 1, 2025 and beyond, particularly for behavioral health in-person visit requirements and audio-only coverage. The permanent redefinition of "interactive telecommunications system" to include audio-only for home-based patients provides a limited but durable floor after the extension expires.